Lite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market Operations
Read moreLite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market Operations
Read moreLite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026
Read moreOncology Focused, Patient Centric
We are committed to the development of novel and differentiated cancer therapies intended to overcome known drug resistance mechanisms in combination with standard-of-care therapies to provide improved outcomes to patients.
